Timely intervention in HMG-CoA Lyase deficiency: The role of newborn screening, metabolic management, and genomic sequencing

Authors

Iskren Menkovic, Department of Pathology and Laboratory Medicine, Children's National Hospital; George Washington University, Washington, DC, USA.
Neelam Makhijani, Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA.
Ludmila Francescatto, Department of Pathology, Duke University Health System, Durham, NC, USA.
Surekha Pendyal, Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA.
Christine Stanley, Variantyx, Inc. 1671 Worcester Road, Suite 400, Framingham, MA, USA.
Sarah P. Young, Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA.
Dwight D. Koeberl, Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA.
Dmitriy Niyazov, Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA.
Ashlee R. Stiles, Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA.

Document Type

Journal Article

Publication Date

12-1-2025

Journal

Molecular genetics and metabolism reports

Volume

45

DOI

10.1016/j.ymgmr.2025.101278

Keywords

3-hydroxy-3-methylglutaryl-CoA Lyase deficiency; Elevated Glycine; Genome sequencing; Newborn screening; RNA expression analysis; Urine organic acids

Abstract

3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase deficiency is a rare autosomal recessive metabolic disease caused by variants in the HMGCL gene leading to an impairment in leucine catabolism and ketone synthesis. In the United States, HMG-CoA lyase deficiency is listed on the recommended uniform screening panel as a core condition for newborn screening. A positive newborn screen will typically show an elevation of C5-hydroxylated species on the acylcarnitine profile using a dried-blood spot collected between 24 and 48 h of life. Initial follow-up testing generally includes a plasma acylcarnitine profile and a urine organic acid profile. Clinically, this metabolic alteration can lead to severe metabolic decompensation, presenting as hypoketotic hypoglycemia and, when left untreated, potential long-term neurological impairments. This report highlights the case of a 38-day-old male with an initial abnormal newborn screen. Follow-up testing showed moderate elevations of C5-hydroxylated and C6-dicarboxylated species on the plasma acylcarnitine profile and marked elevations of 3-hydroxy-3-methylglutaric acid, 3-methylglutaconic acid, 3-methylglutaric and 3-hydroxyisovaleric acid detected by urine organic acid analysis. These findings were consistent with a biochemical diagnosis of HMG-CoA lyase deficiency. Confirmatory molecular testing included targeted HMGCL sequencing including deletion/duplication analysis; the results of which were negative. Genome sequencing was then requested which identified a deep intronic complex variant of unknown significance within intron 1 of HGMCL. RNA sequencing studies were sent as follow-up which revealed that the level of expression of the HMGCL gene was negligible in comparison with tissue-matched controls, thus confirming the biochemical diagnosis of HMG-CoA lyase deficiency.

APA Citation

Menkovic, Iskren; Makhijani, Neelam; Francescatto, Ludmila; Pendyal, Surekha; Stanley, Christine; Young, Sarah P.; Koeberl, Dwight D.; Niyazov, Dmitriy; and Stiles, Ashlee R., "Timely intervention in HMG-CoA Lyase deficiency: The role of newborn screening, metabolic management, and genomic sequencing" (2025). GW Authored Works. Paper 8474.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/8474

Department

Pathology